Bruker Corporation $BRKR Stock Holdings Cut by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. has reduced its stake in Bruker Corporation by 0.9%, selling 100,656 shares, and now owns approximately 10.55 million shares valued at around $440 million.
• Several large investors, including Insigneo Advisory Services and New York State Teachers Retirement System, have increased their positions in Bruker recently, indicating ongoing institutional interest.
• Bruker reported a quarterly earnings miss with $0.32 EPS against a $0.33 estimate, and revenue of $797.4 million, reflecting a 0.4% year-over-year decline.

Vanguard Group Inc. lowered its position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 0.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,550,197 shares of the medical research company's stock after selling 100,656 shares during the quarter. Vanguard Group Inc. owned about 6.96% of Bruker worth $440,365,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of BRKR. Pinnacle Bancorp Inc. acquired a new stake in Bruker during the first quarter valued at approximately $29,000. Allworth Financial LP raised its stake in Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after buying an additional 364 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Bruker during the first quarter valued at approximately $42,000. MassMutual Private Wealth & Trust FSB raised its stake in Bruker by 274.9% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after buying an additional 800 shares in the last quarter. Finally, Fifth Third Bancorp grew its holdings in shares of Bruker by 54.2% during the first quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock valued at $46,000 after purchasing an additional 390 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Stock Performance

BRKR stock traded down $1.11 on Wednesday, reaching $33.73. The company's stock had a trading volume of 2,614,514 shares, compared to its average volume of 3,564,653. Bruker Corporation has a 52 week low of $30.00 and a 52 week high of $72.94. The company has a market capitalization of $5.12 billion, a P/E ratio of 64.87, a price-to-earnings-growth ratio of 2.88 and a beta of 1.16. The firm has a fifty day moving average of $38.66 and a two-hundred day moving average of $41.35. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same period last year, the company earned $0.52 earnings per share. The business's quarterly revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Barclays lowered their target price on Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Monday, August 4th. Bank of America lowered their target price on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Wells Fargo & Company lowered their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the company a "buy" rating in a report on Monday, August 4th. Finally, Citigroup lowered their target price on Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Bruker currently has an average rating of "Hold" and a consensus target price of $51.30.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien purchased 2,608 shares of the firm's stock in a transaction on Friday, June 6th. The stock was purchased at an average cost of $38.36 per share, with a total value of $100,042.88. Following the purchase, the chief executive officer owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 27.30% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.